The efficacy of EP21 in inhibiting the pathogenesis of myopia was further evaluated in a TGF-β2-induced myopia model,24,25 wherein EP21 was orally administered daily to EP21 only (rats without TGF-β2 administration) and TGF-β2 + EP21 rats for 21 days. The gene discussed is TGFB2; the disease is myopia.